Next Generation Cancer Diagnostics Market: Innovation-Driven Growth and Future Opportunities According to a newly published market research report by 24LifeSciences, global next generation cancer diagnostics market was valued at USD 8,060 million in 2026 and is projected to reach USD 28,120 million by 2034, growing at a compound annual growth rate (CAGR) of 20.0% during the forecast period. Next generation cancer diagnostics represent a paradigm shift from traditional histopathology. These advanced technologies enable highly sensitive and specific analysis of cancer biomarkers from various biological samples, with key platforms including Next Generation Sequencing (NGS), qPCR & Multiplexing, and DNA Microarrays. These tools are fundamental for applications such as early detection, companion diagnostics, treatment selection, and minimal residual disease monitoring, enabling a more precise and personalized approach to oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8895/next-generation-cancer-diagnostics-market

Metabolic Biomarker Testing Market Size to Reach USD 22.8 Billion by 2032 | Growth Trends & Forecasts Global metabolic biomarker testing market is experiencing robust growth as healthcare systems increasingly prioritize precision diagnostics, early disease detection, and individualized treatment strategies. Valued at USD 11.3 billion in 2024, the market is expected to expand from USD 12.5 billion in 2025 to USD 22.8 billion by 2032, registering a Compound Annual Growth Rate (CAGR) of 8.7% during the forecast period. This strong trajectory highlights the growing clinical and commercial importance of metabolic biomarkers in modern healthcare and life sciences. Access the market report https://www.24lifesciences.com/metabolic-biomarker-testing-market-9530